Yelin Lapidot Holdings Management Ltd. Has $8.72 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Yelin Lapidot Holdings Management Ltd. lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 395,504 shares of the company’s stock after selling 126,440 shares during the period. Teva Pharmaceutical Industries makes up approximately 1.5% of Yelin Lapidot Holdings Management Ltd.’s holdings, making the stock its 18th biggest position. Yelin Lapidot Holdings Management Ltd.’s holdings in Teva Pharmaceutical Industries were worth $8,717,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in TEVA. Stifel Financial Corp raised its holdings in Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after acquiring an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. increased its stake in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after purchasing an additional 33,277 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,218 shares during the last quarter. Sio Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $24,314,000. Finally, Pinnbrook Capital Management LP bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth approximately $4,966,000. Institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on TEVA shares. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Trading Down 2.7 %

TEVA stock opened at $16.32 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The stock has a market capitalization of $18.49 billion, a price-to-earnings ratio of -11.26, a P/E/G ratio of 1.44 and a beta of 0.71. The business has a fifty day moving average price of $19.75 and a 200 day moving average price of $18.48. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.